Cancer Spurred by the Pattern of Human Life
Disease November 5th, 2010
Cancer is a disease caused by manmade factors of modern life, an ancient study has found.
Tumors are rarely discovered until recently when the pollution and diet become an issue, the assessment was based on the mummies, fossils, and classical literature.
A deep understanding of its origin can treat the disease, which claimed more than 150 thousand inhabitants live in the UK.
Michael Zimmerman, a visiting professor at Manchester University said: “In an ancient society minimal surgical intervention, evidence of cancer must remain in all cases.
“The absence of clear evidence of malignancy in the mummy is interpreted as the strangeness of them in ancient times, it shows that the factors that cause cancer is limited to people who are influenced by modern industrialization.”
To trace the roots of cancer, Professor Rosalie David Zimmerman and his colleagues analyzed the references that may cause disease in classical literature and studied the signs in the fossil record and in the mummified body.
Although the tissue slices from hundreds of Egyptian mummies that were preserved and placed under the microscope, only one case of cancer has been confirmed.
Although the experiment showed that the tumor is better preserved by mummification of healthy tissue.
Rejecting the argument that the ancient Egyptians did not live long enough to develop cancer, the researchers showed that age-related diseases such as hardening of the arteries and weakened bones occur.
Read the rest of this entry »
Vaccines for cancer cells
Cancer December 12th, 2009

cancer treatment still leaves some cancer cells in the body that are not killed. Now there is a vaccine to eliminate cancer cells that remained in the patients, especially chronic myeloid leukemia (chronic myeloid leukemia / CML).
This vaccine can help some patients with CML who took the drug Gleevec. But the researchers revealed that the results of this research is still tentative or not yet reached the final.
This research is funded by the National Institutes of Health and led by Dr. Hyam Levitsky, a professor yaiu oncology, medicine and urology from the Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland. The results of this research has appeared in the journal Clinical Cancer Research.
Gleevec drug marketed by Novartis as Gleevec in the U.S. and Glivec in Europe and Australia, is one of the targeted cancer drugs successfully treat patients with CML.
These drugs are destroying most of the cancer cells, but for certain patients the cancer cells can still be detected by using a sensitive molecular test. The remaining cancer cells can cause the growth of the cancer returning.
Researchers explain the majority of patients with CML in the Gleevec should consume most of his life, although approximately 90 percent of patients get relief. But about 10-15 percent of patients can not tolerate for long-term use.
Levitsky disclose this vaccine is made to shine CML cells that do not turn into cancer. After that change the genetic material of these cells to produce immune system stimulators known as GM-CSF (granulocyte-macrophage colony-stimulating factor) is a substance that can help make white blood cells a particular type.
These cells will also carry antigens that would destroy the CML cells are still circulating in the body. Researchers involving 19 CML patients who were given the vaccine. All patients measured by its level of CML cells and have been taking Gleevec for more than 12 months. Patients are given the vaccine with 4 times the chance of 10 shots in every opportunity.
Cells acquired the remaining cancer has decreased, ie 12 patients found to reach the lowest levels of the cancer cells remaining, and 7 other people is not detected at all remaining cancer cells in the body.
But the researchers realized that the study is still limited, such as the limited number of patients and the lack of comparison with other therapies.
Because it still needs further research to ensure that this vaccine can actually lower the cancer cells that remain. The test was conducted also show side effects such as pain at the injection site, swelling, sometimes pain in the muscles and a mild fever.













